Author: conor

Research Underpins Clinical Practice: Take a Look at a Few of the Abstracts Highlighted from ASTRO 2022

This year at ASTRO over 1,600 abstracts were accepted, representing all aspects of oncology and radiation therapy for oncologic and non-oncologic conditions. The extensive breadth and depth of abstracts underscores the importance clinicians worldwide place on radiation therapy related research. With a focus on CyberKnife® and TomoTherapy®/Radixact® Treatment Delivery Systems, we have highlighted some abstracts […]

Making Adaptive Radiotherapy Practical for Mainstream Use

Adaptive radiotherapy (ART) has long been viewed as the inevitable future of radiotherapy. Patients are living, breathing implying dynamic “targets” and tumors that can change significantly over treatment fractions. But in a world where optimizing patient volume is key both from a public health and economic perspective, what does the future of ART look like? […]

Accuray expands personalized breast cancer treatments this Pink October

As we recognize Breast Cancer Awareness Month this October, we’ll start with the facts. Last year, breast cancer overtook lung cancer to become the most commonly-diagnosed global cancer. The World Health Organization (WHO) reports breast cancer accounts for 12% of all new annual cancer cases worldwide1. To make that personal, 1 in 8 women will […]

PACE-B prostate cancer study demonstrates reduced toxicity with CyberKnife® ultra-hypofractioned SBRT

Clinical teams around the globe are leveraging the CyberKnife Treatment Delivery System to open up completely new possibilities in ultra-hypofractionated radiation therapy. Research has already shown that using the CyberKnife System to deliver ultra-hypofractionated stereotactic body radiation therapy (SBRT) can achieve excellent cancer control — with survival rates, toxicity and incidences of side effects equal to, […]